Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 13 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Tsolaki, Eleftheria  [Clear All Filters]
Journal Article
Kotoula, V., Bobos M., Alexopoulou Z., Papadimitriou C., Papadopoulou K., Charalambous E., et al. (2014).  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.. PLoS One. 9(8), e103707.
Batistatou, A., Kotoula V., Bobos M., Kouvatseas G., Zagouri F., Tsolaki E., et al. (2018).  Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.. Clin Breast Cancer. 18(1), 53-62.e3.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Razis, E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., et al. (2014).  EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.. J Cancer Res Clin Oncol. 140(5), 737-48.
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Koutras, A., Lazaridis G., Koliou G-A., Kouvatseas G., Christodoulou C., Pectasides D., et al. (2018).  Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.. PLoS One. 13(12), e0207707.
Kotoula, V., Lyberopoulou A., Papadopoulou K., Charalambous E., Alexopoulou Z., Gakou C., et al. (2015).  Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA.. PLoS One. 10(6), e0128818.
Kotoula, V., Fostira F., Papadopoulou K., Apostolou P., Tsolaki E., Lazaridis G., et al. (2017).  The fate of BRCA1-related germline mutations in triple-negative breast tumors.. Am J Cancer Res. 7(1), 98-114.
Kotoula, V., Bobos M., Vassilakopoulou M., Tsolaki E., Chrisafi S., Psyrri A., et al. (2015).  Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).. Appl Immunohistochem Mol Morphol. 23(1), 60-70.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Fountzilas, G., Psyrri A., Giannoulatou E., Tikas I., Manousou K., Rontogianni D., et al. (2018).  Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.. Int J Cancer. 142(1), 66-80.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., et al. (2019).  Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.. Clin Breast Cancer. 19(2), 113-125.e4.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.